Suggestions
Ben van Zwanenberg
Business Manager - Bioinformatics and R&D at Hays
Ben van Zwanenberg is a seasoned professional in the life sciences recruitment industry, with a focus on pharmaceutical, medical technology, and biotech sectors.
As an Executive Search expert, Ben specializes in Senior roles, Headhunting, Project Delivery, and Niche and technical appointments within the bioinformatics and pharmaceutical R&D market.
He is adept at identifying and placing top talent including Bioinformaticians, Computational Biologists, Statistical Geneticists, Statisticians, Real World Data & Real World Evidence specialists, Project Managers, Directors, Scientific Programmers, Development Biologists, and Computational Drug Discovery Scientists.
Ben's educational background includes a degree in MChem, Chemistry from the University of Oxford, and he has also studied at RGS Newcastle.
With prior roles as Business Manager, Expert in Residence, Principal Recruitment Consultant, Senior Recruitment Consultant at Hays, and Scientific Consultant at Key People, Ben possesses a wealth of experience and knowledge in the field.
For recruitment needs or career opportunities in the life sciences realm, Ben can be reached at +44 0203 465 0057 or [email protected].
Highlights
🚀 Biotech Fundraising Soars in 2024! 🚀 The biotech sector has seen a remarkable surge in fundraising and financing in 2024, outpacing 2023 by a significant margin. This year, we’ve witnessed groundbreaking deals and substantial capital inflows that are set to drive innovation and transformation in human health and sustainability.
🌟 Highlights of 2024: J.P. Morgan launched its first biotech venture capital fund, raising over $500 million to support innovative biotech companies. Flagship Pioneering secured a whopping $3.6 billion to fuel breakthrough innovations, aiming to create 25 new companies focused on human health, sustainability, and AI.
📈 Funding Growth: In the first half of 2024, venture investments in biopharma reached $14.1 billion, compared to $11.5 billion in the same period of 2023. Biopharma IPOs in the first half of 2024 totalled $23 billion, significantly higher than the $15 billion raised in the second half of 2023.
These impressive fundraising efforts reflect the growing confidence and investment in the biotech sector. With such robust financial backing, the industry is poised for unprecedented growth and advancements.
#biotech #fundraising #healthcare #investment #lifesciences #research #development #funding #IPO
Very privileged to have spent yesterday evening watching the cricket 🏏 and talking to cricketing legend Mark Ramprakash about coaching, how to stay at the top of your game (and what to do when things don't go to plan) and, of course, Strictly! 🕺💃 Among the many pearls of wisdom were two very sage bits of advice: Do it for the love of it - whether it's sport, hobbies, career or otherwise, as this will help you through the tough times. And don't annoy Merv Hughes when he's bowling rockets...
#sport #cricket #careeradvice #performance
